Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine

Research Communications in Molecular Pathology and Pharmacology

Volumn 98, Issue 3, 1997, Pages 273-292

  Kishimoto, Wataru ^a,b   Hiroi, Toyoko ^b   Sakai, Kenji ^a   Funae, Yoshihiko ^b   Igarashi, Takashi ^a  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; CHLORZOXAZONE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DRUG METABOLITE; EPINASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST; OXYGENASE; RECOMBINANT PROTEIN; TERFENADINE; TESTOSTERONE; THEOPHYLLINE; TOLBUTAMIDE;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; KINETICS; LIVER MICROSOME; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DIBENZAZEPINES; HISTAMINE H1 ANTAGONISTS; HUMANS; IMIDAZOLES; INTESTINE, SMALL; ISOENZYMES; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS; TERFENADINE;

EID: 0031433960     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Backman, J.T., Olkkola, K.T. and Neuvonen, P.J. (1996). Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59, 7-13.
2. Boehringer Ingelheim. (1994). Pharmacokinetics of Alesion. In : Interview form of Alesion. Boehringer Ingelheim. Kawanishi, Hyogo Japan, pp. 23-25.
3. C-Bowden, A. (1995). Fitting the Michaelis-Menten equation by least squares. In : Analysis of Enzyme Kinetic Data. Oxford University Press. Walton St. Oxford UK. pp. 27-36.
4. Davies, A.J., Harindra, V., McEwan, A. and Ghose, R.R. (1989). Cardiotoxic effect with convulsions in terfenadine overdose, Br. Med. J. 298, 325.
5. Füegner, A., Bechtel, W.D., Kuhn, F.J. and Mierasu, J. (1988). In vitro and in vivo studies of the non-sedating antihistamine epinastine. Arzneim-Forsch Drug Res. 38, 1446.
6. Funae, Y. and Imaoka, S. (1987). Purification and characterization of liver microsomal cytochrome P-450 from untreated male rats. Biochim. Biophys. Acta. 926, 349-358.
7. Garteiz, D.A., Hook, R.H., Walker, B.J. and Okerholm, R.A. (1982). Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim.-Forsch. Drug Res. 32, 1185-1190.
8. Gomez, D.Y., Wacher, V.J., Tomlamovich, S.J., Hebert, M.F. and Bonet, L.Z. (1995). The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporin. Clin. Pharmacol. Ther. 58, 15-19.
9. Herbert, M.F., Roberts, J.P., Pruekaaritanont, T. and Benet, L.Z. (1992). Bioavailability of cyclosporin with concomitant refampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52, 453-457.
10. Hiroi, T., Ohishi, N., Imaoka, S., Yabusaki, Y, Fukui, H. and Funae. Y. (1995). Mepyramine, a histamine HI receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. J. Pharmacol. Exp. Ther. 272, 939-944.
11. Honig, P.K., Wortham, D.C., Hull, R., Zamani, K., Smith, J.E. and Cantilena, L.R. (1993a). Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J. Clin. Pharmacol. 33, 1201-1206.
12. Honig, P.K., Worthan, D.C., Zamani, K., Conner, D.P., Mullin, J.C. and Cantilena, L.R. (1993b). Terfenadine-ketoconazole interaction: Pharmacokinetic and electrocardiographic consequences. JAMA 269, 1513-1518.
13. J.-Romet, M. Crawford, K., Cyr, T. and Inaba, T. (1994). Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotic and azole antifungals. Drug Metab. Dispos. 22, 849-857.
14. Kivistö, K.T., Neuvonen, P.J. and Klotz, U. (1994). Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clin. Pharmacokinet. 27, 1-5.
15. Ling, K.-H.J., Leeson, G.A., Burmaster, S.D., Hook, R.H., Reith, M.K. and Cheng, L.K. (1995). Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes. Drug Metab. Dispos. 23, 631-636.
16. McTavish, D., Goa, K.L., and Ferrill, M. (1990). Terfenadine: an updated review of its pharmacologocal properties and therapeutic efficiency. Drugs 39, 552-574.
17. Monahan, B.P., Ferguson, C.L., Killeavy, E.S., Lloyd, B.K., Troy, J. and Cantilena Jr, R. (1990). Torsades de pointes occurring in association with terfenadine use. J. Am. Med. Assoc. 264, 2788-2790.
18. Nakamura, K., Yokoi, T., Inoue, K., Shimada, N., Ohashi, N., Kume, T. and Kamataki, T. (1996). CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine HI antagonist promethazine in human liver microsomes. Pharmacogenetics 6, 449-457.
19. Nicholson, A.N. (1987). New antihistamine free of sedative side effects. Trends Pharmacol. Sci. 8, 247-249.
20. Ohtani, H., Kotaki, H., Sawada, Y. and Iga, T. (1996). A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats. J. Pharm. Pharmacol. 49, 458-462.
21. Peter, R., Bocker, R., Beaune, P.H., Iwasaki, M., Guengerich, F.P. and Yang, C.S. (1990). Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE-1. Chem. Res. Toxicol. 3, 566-573.
22. Peters, W.H.M. and Kremen, P.G. (1989). Cytochrome P450 in the intestinal mucosa of man. Biochem. Pharmacol. 38, 1535-1538.
23. Pruekaaritanont, T., Gorham, L.M., Hochman, J.H., Tran, L.O. and Vyas, K.P. (1996). Comparative studies of drug metabolizing enzymes in dog, monkey, and human small intestines, and in CACO-2 cells. Drug Metab. Dispos. 24, 634-642.
24. Rasmussen, B.B., Nielsen, K.K. and Brosen, K. (1994). Determination of theophylline metabolites in human liver microsomes by high-performance liquid chromatography. Anal. Biochem. 222, 9-13.
25. Rau, S.E., Bend, J.R., Arnold, J.M.O., Tran, L.T., Spence, J.D. and Bailey, D.G (1997). Grapefruit juice-terfenadine single-dose interaction: Magnitude, mechanism, and relevance. Clin. Pharmacol. Ther. 61, 401-409.
26. Relling, M.V., Aoyama, T., Gonzalez, F.J. and Meyer, U.A. (1990). Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252, 442-447.
27. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. and Guengerich, F.P. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423.
28. Simons, F.E.R. and Simons, K.J. (1994). The pharmacology and use of H1-receptor-antagonist drugs. N. Engl. J. Med. 330, 1663-1670.
29. Sorkin, E.M, and Heel, R.C. (1985). Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29, 34-56.
30. Woodward, J.K. (1988). Pharmacology and toxicology of nonclassical antihistamines. Cutis 42, 5-9.
31. Woodward, J.K. and Munro, N.L. (1982). Terfenadine, the first non-sedating antihistamine. Arzneim.-Forsch. Drug Res. 32, 1154-1156.
32. Woosley, R.L. (1996). Cardiac actions of antihistamines. Ann. Rev. Pharmacol. Toxicol. 36, 233-252.
33. Yun, C.-H., Okerholm, R.A. and Guengerich, F.P. (1993). Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P450 3A(4) in N-dealkylation and C-hydroxylation. Drug Metab. Dispos. 21, 403-409.